Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Head & neck cancer

912MO - A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study


18 Sep 2020


Mini Oral - Head & neck cancer


Cytotoxic Therapy;  Immunotherapy

Tumour Site

Head and Neck Cancers


Li Zhang


Annals of Oncology (2020) 31 (suppl_4): S599-S628. 10.1016/annonc/annonc277


L. Zhang1, Y. Yang1, X. Chen2, J. Li3, J. Pan4, X. He5, L. Lin6, Y. Shi7, W. Feng8, J. Xiong9, K. Yang10, Q. Yu11, D. Hu12, Y. Sun13, Q. Zhang14, G. Hu15, P. Li16, L. Shen17, Q. Yang18, B. Zhang18

Author affiliations

  • 1 Oncology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Head & Neck Radiotherapy, Zhejiang Cancer Hospital, 310000 - Hangzhou/CN
  • 3 Head-neck Radiotherapy Department, Jiangxi Cancer Hospital, 330029 - Nanchang/CN
  • 4 Department Of Head & Neck Radiation Oncology, Fujian Provincial Cancer Hospital, 350014 - Fuzhou/CN
  • 5 Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, 100021 - Beijing/CN
  • 6 Tumor Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, 510400 - Guangzhou/CN
  • 7 The Head And Neck Radiotherapy Department Ii, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013 - Changsha/CN
  • 8 Department Of Head, Neck And Chest Cancer, Foshan First People's Hospital, 528000 - Foshan/CN
  • 9 Department Of Oncology, The First Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
  • 10 Cancer Center, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, 430022 - Wuhan/CN
  • 11 Respiratory Oncology, Guangxi Medical University Affiliated Tumor Hospital, 530021 - Nanning/CN
  • 12 Radiation Therapy Center, Hubei Cancer Hospital, 430070 - Wuhan/CN
  • 13 Radiation Oncology Department, Beijing Cancer Hospital, 100036 - Beijing/CN
  • 14 Medical Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 15 The Department Of Cancer, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 430000 - Wuhan/CN
  • 16 Ward 1 Of Oncology, West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 17 Oncology, Xiangya Hospital Central South University, 410008 - Changsha/CN
  • 18 Clinical Research & Development, Jiangsu Hengrui Medicine Co., Ltd, 201210 - Shanghai/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 912MO


The management of R/M NPC remains a challenge worldwide due to its poor prognosis and limited treatment option after prior chemotherapy. Camrelizumab, a humanized anti–PD-1 antibody, had shown favorable anti-tumor activity and manageable toxicities in R/M NPC in previous phase I trial (Fang et al. Lancet Oncol 2018). We conducted this phase II trial (CAPTAIN) to further assess the efficacy and safety of camrelizumab in R/M NPC.


Patients with histologically confirmed R/M NPC (stage IVb) who had progressed on ≥2 lines of chemotherapy were enrolled and received camrelizumab at 200 mg IV q2w. The primary endpoint was ORR assessed by independent review committee (IRC) per RECIST v1.1.


From Aug 14, 2018 to Dec 30, 2019, 156 eligible patients were enrolled and received camrelizumab treatment. As of data cutoff on Mar 31, 2020, the median follow-up time was 9.2 months (range 0.7–19.1). Of the 156 patients, 44 (28.2%, 95% CI 21.3–36.0) patients had an objective response assessed by IRC, including one complete response and 43 partial responses. Median DoR was not reached (95% CI 7.4–not estimable), and the 12-month DoR rate was 53.7% (95% CI 30.9–72.0). Median PFS per IRC was 3.7 months (95% CI 2.0–3.9) and median OS was 17.1 months (95% CI 15.2–not estimable). Treatment-related adverse events (TRAEs) of any grade were observed in 151 (96.8%) of the 156 patients. TRAEs of ≥3 grade occurred in 22 (14.1%) patients, with the most common ones being increased gamma-glutamyl transferase (3.2%) and anaemia (3.2%). Treatment interruption and discontinuation due to TRAEs occurred in 18 (11.5%) and one (0.6%) patients, respectively. Seventeen (10.9%) patients had serious TRAEs, and one death was considered as drug-related. Plasma Epstein-Barr virus DNA and evaluable tumor samples for biomarker analysis were obtained and the result will be presented at the meeting.


Camrelizumab demonstrated promising anti-tumor activity and favorable safety profile in patients with R/M NPC who had progressed on ≥2 lines of chemotherapy, thus could represent a novel treatment option for this patient population.

Clinical trial identification

NCT03558191; CTR20180865.

Editorial acknowledgement

Legal entity responsible for the study

Jiangsu Hengrui Medicine Co., Ltd.


Jiangsu Hengrui Medicine Co., Ltd.


Q. Yang, B. Zhang: Full/Part-time employment: Jiangsu Hengui Medicine Co., Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.